The increased levels of PD-L1, B7-H3, and IDO expressions in sHCC cells may play an immunosuppressive role in tumor microenvironment, suggesting that co-targeting PD-L1 along with other immune checkpoints may be a potential strategy to treat patients with sHCC. Here, IDO1 is linked to neoplasm.